Safety and Efficacy of Two Types of Influenza Vaccination in Heart Transplant Recipients: A Prospective Randomised Controlled Study

Magnani, Gaia; Falchetti, Elena; Pollini, Gian Matteo; Reggiani, Maria Letizia Bacchi; Grigioni, Francesco; Coccolo, Fabio; Potena, Luciano; Magelli, Carlo; Sambri, Vittorio; Branzi, Angelo

doi:10.1016/j.healun.2004.03.004

Cited by 73 publications

(54 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Figure S1). In a single patient (1.6%) (10,26,(29)(30)(31)(32)(33). Furthermore, our data confirm and extend the results of the single study which analyzed postvaccinal HLA antibodies and showed that in heart transplant recipients no significant donor-specific allosensitization was induced by influenza vaccination (30).…”

Section: Anti-influenza Antibodiessupporting

confidence: 85%

Humoral and Cellular Immune Responses after Influenza Vaccination in Kidney Transplant Recipients

Candon

Thervet

Lebon

et al. 2009

American Journal of Transplantation

107

View full text Add to dashboard Cite

Section: Anti-influenza Antibodiessupporting

confidence: 85%

Humoral and Cellular Immune Responses after Influenza Vaccination in Kidney Transplant Recipients

Candon

Thervet

Lebon

et al. 2009

American Journal of Transplantation

107

View full text Add to dashboard Cite

“…No clinical evidence for rejection or graft dysfunction following immunization has been reported in studies that have specifically looked at this outcome (31,34,(58)(59)(60). Three studies have investigated the development of donor specific antibodies (DSA) after vaccination.…”

Section: Effects Of Vaccination Including Allograft Dysfunctionmentioning

confidence: 99%

Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations

Kumar

Blumberg

Danziger‐Isakov

et al. 2011

American Journal of Transplantation

154

164

View full text Add to dashboard Cite

Influenza virus causes a spectrum of illness in transplant recipients with a high rate of lower respiratory disease. Seasonal influenza vaccination is an important public health measure recommended for transplant recipients and their close contacts. Vaccine has been shown to be safe and generally well tolerated in both adult and pediatric transplant recipients. However, responses to vaccine are variable and are dependent on various factors including time from transplantation and specific immunosuppressive medication. Seasonal influenza vaccine has demonstrated safety and no conclusive evidence exists for a link between vaccination and allograft dysfunction. Annually updated trivalent inactivated influenza vaccines have been available and routinely used for several decades, although newer influenza vaccination formulations including high-dose vaccine, adjuvanted vaccine, quadrivalent inactivated vaccine and vaccine by intradermal delivery system are now available or will be available in the near future. Safety and immunogenicity data of these new formulations in transplant recipients requires investigation. In this document, we review the current state of knowledge on influenza vaccines in transplant recipients and make recommendations on the use of vaccine in both adult and pediatric organ transplant recipients.

show abstract

“…[19][20][21] Its safety and efficacy in liver transplant and other solid-organ recipients have been proven in several studies. 19,[21][22][23][24][25] Although our case suggests that GBS may occur in liver transplant recipients after influenza vaccination, the very low incidence of vaccine-associated GBS, the significantly increased complications from influenza virus infection in solid organ recipients, and the rise of influenza drug resistance make influenza vaccination the first-line strategy for influenza virus infection prevention in solid-organ recipients. 26,27 This fact is supported by the current guidelines for vaccination of solid-organ recipients.…”

Section: Discussionmentioning

confidence: 80%

Guillain-Barré syndrome triggered by influenza vaccination in a recipient of liver transplant on FK506

Moon

Souayah

2006

Liver Transpl

View full text Add to dashboard Cite

Guillain-Barré syndrome (GBS) has been rarely reported after liver transplantation and generally has good outcome. We report a liver transplant patient on FK506 (tacrolimus) who developed GBS 6 months after liver transplantation. There was no evidence of liver rejection or active infection. Despite treatment with intravenous immunoglobulin, the patient expired. GBS occurred despite downregulation of T cells by FK506, suggesting that humoral dysfunction might be the predominant mechanism of GBS in this report . Liver Transpl 12:1537-1539, 2006

show abstract

Safety and Efficacy of Two Types of Influenza Vaccination in Heart Transplant Recipients: A Prospective Randomised Controlled Study

Cited by 73 publications

References 24 publications

Humoral and Cellular Immune Responses after Influenza Vaccination in Kidney Transplant Recipients

Humoral and Cellular Immune Responses after Influenza Vaccination in Kidney Transplant Recipients

Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations

Guillain-Barré syndrome triggered by influenza vaccination in a recipient of liver transplant on FK506

Contact Info

Product

Resources

About